Top Markets
Coin of the day
Adagio Therapeutics, Inc. Adagio Therapeutics, Inc.

Adagio Therapeutics, Inc.

ADGI
Rang in Aktien #16435
Adagio Therapeutics, Inc. is a clinical-stage biopharmaceutical firm, primarily... Adagio Therapeutics, Inc. is a clinical-stage biopharmaceutical firm, primarily focused on the discovery, development, and subsequent commercialization of antibody-based therapeutics designed to combat infectious diseases across the United States. Its most advanced product candidate, ADG20 (adintrevimab), is a neutralizing antibody currently undergoing Phase 3 clinical trials. This antibody is being evaluated for both the treatment and prevention of coronavirus disease. Adagio Therapeutics also engages in strategic collaborations. It partners with Adimab, LLC to facilitate the discovery and optimization of novel proprietary antibodies. Furthermore, the company works with the Scripps Research Institute on research initiatives aimed at identifying vaccine candidates that could prevent, diagnose, or treat influenza and beta coronaviruses. Founded in 2020, Adagio Therapeutics maintains its headquarters in Waltham, Massachusetts.
Aktienkurs
$4.64
Zuletzt synchronisiert: 2022-09-12
Marktkapitalisierung
$293.43M
Veränderung (1 Tag)
0.87%
Veränderung (1 Jahr)
0.00%
Land
US
Handel Adagio Therapeutics, Inc. (ADGI)

Kategorie

Kursverlauf für Adagio Therapeutics, Inc. (ADGI)
Höchster Schlusskurs: $4.63 am 2022-09-01

Niedrigster Schlusskurs: $27.68 am 2021-08-01
Kursverlauf der Aktie von Adagio Therapeutics, Inc. von 2021 bis 2026
Jährliche Kursentwicklung
Jahr Leistung
2022 -78.16%
2021 0.00%
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Aktienkurs Veränderung 1J% Land
$548.15 36.70%
US
$1.03K 45.33%
NL
$153.87 536.09%
US
$121.61 -10.47%
AU
$748.60 6.90%
CH